|Bid||3.9000 x 1000|
|Ask||0.0000 x 3000|
|Day's Range||4.1500 - 4.5900|
|52 Week Range||2.9111 - 6.1900|
|Beta (5Y Monthly)||2.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 4, 2020 - Mar 9, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
Merrimack Pharmaceuticals, Inc. (MACK) (the “Company” or “Merrimack”), announced today that its Board of Directors (the “Board”) has adopted a Section 382 net operating loss rights plan (the “Plan”) and declared a dividend distribution of one Preferred Share Purchase Right on each outstanding share of Company common stock. The Plan is designed to protect the Company’s ability to use its valuable net operating loss (“NOL”) carryforwards and certain other valuable tax attributes. “Preservation of our NOL carryforwards is a key element of our strategic plan and may be used to offset potential corporate tax payments related to future milestones in order to maximize shareholder value,” said Gary Crocker, CEO of the Company.
Merrimack Pharmaceuticals, Inc. (MACK) today announced that it received a $5 million milestone payment from Ipsen, triggered by Ipsen’s decision to progress the ongoing multi-part clinical trial evaluating ONIVYDE in patients with small-cell lung cancer into the second randomized portion of the trial focused on efficacy assessment. As a result of this milestone payment, Merrimack’s Board of Directors has authorized and declared a special cash dividend of $6.7 million on the Company’s common stock (the “Special Dividend”). The Special Dividend is payable on December 23, 2019 to stockholders of record as of the close of business on December 16, 2019.
Attorney and proxy fight expert Kai Liekefett estimated that upwards of 10 percent of public companies have faced activist investor challenges so far this year.
Pleased Involvement Catalyzed Much Needed Change at Merrimack and Intends to Continue to Monitor Situation LAKEWAY, Texas , Sept. 24, 2019 /PRNewswire/ -- JFL Capital Management, LLC (together with its ...
As the US$72m market cap Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) released another year of negative earnings...
Believes Significant Destruction of Value and Lack of Alignment with Stockholders Warrants an Overhaul in the Boardroom Highlights Potential Paths Forward to Unlock Stockholder Value that JFL Capital Nominees ...
CAMBRIDGE, Mass., July 25, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK) today announced that its Board of Directors has authorized and declared a special cash dividend of $20 million on the Company's common stock. The special dividend is payable on September 5, 2019 to stockholders of record as of the close of business on August 28, 2019. The ex-dividend date for the special dividend will be September 6, 2019, the first trading day following the payment date.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 30) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Misonix, ...
CAMBRIDGE, Mass., May 30, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK) today announced the completion of its review of strategic alternatives, following which the Company's Board of Directors is implementing a series of measures designed to extend Merrimack's cash runway into 2027 and preserve its ability to capture the potential remaining ONIVYDE-related milestones resulting from its 2017 asset sale to Ipsen S.A. The Company also announced plans to issue a special cash dividend. The core driver throughout the Company's strategic review process was to optimize value for shareholders, including through the preservation of potential milestone payments that Merrimack is eligible to receive.
CAMBRIDGE, Mass. , May 10, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), an oncology company focused on biomarker-defined cancers, today announced its first quarter 2019 financial ...
The ratings on eight P&I classes were affirmed because the transaction's key metrics, including Moody's loan-to-value (LTV) ratio, Moody's stressed debt service coverage ratio (DSCR) and the transaction's Herfindahl Index (Herf), are within acceptable ranges. The rating on the IO class was affirmed based on the credit quality of the referenced classes. The rating on Cl. PEZ was affirmed due to the credit quality of the referenced exchangeable classes.
Pomerantz LLP is investigating claims on behalf of investors of Merrimack Pharmaceuticals, Inc. (“Merrimack” or the “Company”) (NASDAQ: MACK). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. On April 4, 2019, Merrimack announced the discontinuation of work on its sole drug candidate in clinical trials, MM-310, citing safety issues. Despite amending the protocol for its Phase 1 study after observing and disclosing signs of peripheral neuropathy in clinical trial participants beginning in November, Merrimack reported that subjects taking MM-310 continued to experience weakness, numbness and extremity pain associated with peripheral neuropathy. On this news, Merrimack’s stock price fell $1.18 per share, or 16.41%, to close at $6.01 per share on April 5, 2019.
NEW YORK, NY / ACCESSWIRE / April 8, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Merrimack Pharmaceuticals, Inc. (''Merrimack'' or the ''Company'') ...
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! It is a pleasure to report that the Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is up 58% in the last quarter. But...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 4) AEterna Zentaris Inc. (NASDAQ: AEZS ) GALAPAGOS NV/S ...
CAMBRIDGE, Mass., April 4, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK), an oncology company focused on biomarker-defined cancers, today announced the Company is discontinuing development of MM-310, its antibody-directed nanotherapeutic for the treatment of solid tumors. Based on emerging data since the recent amendment of the clinical protocol, the Company has concluded that the study would not be able to reach an optimal therapeutic index for MM-310.